I'll post it myself....:)Visiomed Secures Major UK Distributor...

I'll post it myself....

:)


Visiomed Secures Major UK Distributor for Funhaler®Initial commitment of 112,000 units during first 2 Years
Agency arrangements include Boots Chemists and Lloyds Pharmacy distribution Contract lifts total committed sales for Funhaler over next 2 years to $6MPlacement to raise $1 million to support international marketing efforts.Visiomed Group Ltd (ASX: VSG) has signed an initial 2-Year Agreement with major
UK medical distributor Clinisupplies Ltd to supply its innovative Funhaler® paediatric incentive asthma spacer throughout major retail pharmacy outlets including Boots
and Lloyds, two of the UK's largest pharmacy chains. Secures Major UK Distributor. The Agreement will see Visiomed supply UK pharmacies
with an initial 32,000 units during Year 1 of the contract and 80,000 units during Year 2,
commencing mid 2007.
Visiomed Chief Executive Officer Dr William Dolphin said: "During the last Quarter we have expanded our distribution network significantly, signing on leading distributors in major
overseas markets including the US and Europe.
"With the addition of Clinisupplies for the UK we now have in excess of US$6 million in
committed sales for the Funhaler in overseas markets during the next 2 years; this is in
addition to strong revenues from the Funhaler and Breath-A-Tech spacers in Australia
where Visiomed is the market-leading spacer manufacturer, and from royalties generated
through our licensing agreement with US-based Respironics."
According to a recent report from the Global Initiative for Asthma (GINA), the UK has one of
the highest prevalence of asthma in the world, with the condition afflicting an estimated
18.4% of the population.
"Presenting the Funhaler®to the major UK market via globally recognised pharmacies like Boots and Lloyds is a significant achievement for Visiomed. With a population of
approximately 61 million and an extremely high prevalence of asthma, the UK is an
important and influential market within the European Community," Dr Dolphin said. "We are
very pleased to be working with a group having the outstanding sales history and healthcare
market penetration of Clinisupplies."
The contract pricing with Clinisupplies, whilst agreed, is conditional upon approval of
proposed pricing by the UK National Health Service Business Services Authority. An application in this regard has been lodged with the BSA by the Company. In the unlikely
event proposed pricing is not approved the contract pricing terms may have to be amended. CliniSupplies is expected to commence UK product sales in mid-2007, assuming Visiomed's
NHS BSA application is successful.
The Funhaler®is already CE Marked and has required regulatory approvals for sale into Europe and the UK.
Placement to Raise $1 Million. The Company is pleased to confirm a Placement of 60
million shares at 1.7 cents to sophisticated investors. The Placement will raise
approximately AU$1 million (net of costs) and includes 1:3 attaching unlisted options at 2.5 cents expiring in 18 months. Following the Placement the Company will have cash and
cash equivalents of approximately AU$2.4 million. The funds raised will supplement existing working capital and will be applied primarily to the expansion of overseas distribution of the
Funhaler®asthma spacer into the USA and European markets.